ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ARCB vs TMO // GROSS PROFIT MARGIN

ArcBest Corporation (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ARCB 3 — TMO 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARCB VS. TMO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ARCB TMO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 5.40% 9.30% -3.90 TMO /roic <GO>
EV/EBITDA & P/E Valuation 15.2x 30.4x -15.20 ARCB /valuation <GO>
Free Cash Flow Yield 4.04% 2.40% +1.64 ARCB /fcf-yield <GO>
Operating Margin 2.30% 17.40% -15.10 TMO /operating-margins <GO>
Net Profit Margin 1.50% 15.10% -13.60 TMO /net-margins <GO>
Revenue Growth (YoY) -4.00% 3.90% -7.90 TMO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.39% 0.24% +0.15 ARCB /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 4.50 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 TMO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.9 62.9 -21.00 TMO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.94 — TIE /macro-sensitivity <GO>
Forward P/E Multiple 43.7x 36.3x +7.40 TMO /forward-pe <GO>
Enterprise Scale & Market Cap $2.83B $262.22B -$259.39B TMO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ARCB REV TMO REV ARCB GROSS % TMO GROSS % ARCB FCF TMO FCF
FY 2025 $4.01B $44.56B — — $114.2M $6.29B
FY 2024 $4.18B $42.88B — — $62.7M $7.27B
FY 2023 $4.43B $42.86B — — $322.2M $6.48B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARCB // BETA —
TMO // BETA 0.94